Key Market Indicators
Sales of blood and blood forming organs medicine in New Zealand is expected to reach $75.4 million in 2026, a 2.4% year-on-year growth since 2021. This is an increase of 1.8% since 1998 when the market was valued at $64.6 million. New Zealand ranked 24th globally in 2021, with Slovenia coming in ahead with $64.6 million. Germany, Italy and South Korea followed in 2nd, 3rd and 4th place respectively. There is also an expected increase in anemia prevalence in New Zealand, reaching 3,270 hospital discharges by 2026, up 1.1% year-on-year from 2021. This is a 1% increase since 2005 when the demand was at 3,060 hospital discharges. New Zealand ranked 27th globally in 2021, with Switzerland coming in ahead with 3,060 hospital discharges. Germany, the United Kingdom and Poland followed in 2nd, 3rd and 4th place respectively.
